Our lab has previously reported that PRMT5 cooperates with its cofactor PICln in the epigenetic upregulation of genes that take part in DDR and contribute to the radioresistance acquisition in prostate cancer cells. This evidence concerns the gene PRMT5 and prostate carcinoma.